- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: EPA and Drinking Water; Teens Seek Vaccines; Companies Cut Praluent Price
The Environmental Protection Agency (EPA) is expected to make a decision soon regarding stricter regulations of polyfluoroalkyl compounds, or PFAS, which are chemicals in coatings meant to protect consumer goods from stains, water, and corrosion that have been found in drinking water; teenagers are turning to Reddit and other sites to figure out how to get vaccinated if their parents subscribe to antivaccine beliefs; Regeneron and Sanofi announced they are cutting the price of its proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab (Praluent).
Decision From EPA Expected Soon on Chemical Regulations Affecting Health
The Environmental Protection Agency (EPA) is expected to make a decision soon regarding stricter regulations of polyfluoroalkyl compounds, or PFAS, which are chemicals in coatings meant to protect consumer goods from stains, water, and corrosion, The Associated Press reported. Increasing numbers of states have found them seeping into water supplies; studies have indicated links between the chemicals and excessive cholesterol levels, ulcerative colitis, thyroid disease, testicular and kidney cancer, problems in pregnancies, low birth weight, and liver problems.
Teens From Homes With Antivaccine Beliefs Turning to Internet to Figure Out How to Get Vaccinated
Teenagers are turning to Reddit and other sites to figure out how to get vaccinated if their parents subscribe to antivaccine beliefs, The Washington Post reported. The paper detailed the pursuit of an Ohio teen who started to get his vaccinations done last fall, but the 18-year-old is afraid for his younger siblings.
Regeneron, Sanofi Cutting Price of Praluent by 60%
Regeneron and Sanofi announced they are cutting the price of its proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab (Praluent) by 60% in the United States. The companies said that the new list price will be $5850 annually in early March for both the 75 mg and 150 mg doses.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
